Your trusted source for investing success

Tag: pharmaceutical ingredients

Looking for Cannabis Stocks?

Read our report to find market data, important news and stocks to watch!
 

Cambrex Reports Fourth Quarter and Full Year 2017 Financial Results

Cambrex (NYSE:CBM), a leading manufacturer of small molecule innovator and generic Active Pharmaceutical Ingredients (APIs), reports results for the fourth quarter and full year ended December 31, 2017.

As quoted in the press release:
Net revenue increased 2.5% to $182.3 million compared to $177.9 million in the same quarter last year.  Excluding the

Lexaria Bioscience Receives U.S. Patent Award for its DehydraTECH(tm) Delivery of THC, NSAIDs, Nicotine and Vitamins

Lexaria Bioscience Receives U.S. Patent Award for its DehydraTECH(tm) Delivery of THC, NSAIDs, Nicotine and Vitamins

Lexaria Bioscience Corp. (OTCQB: LXRP) (CSE: LXX) (the “Company” or “Lexaria”) a drug delivery platform innovator, announces the United States Patent and Trademark Office (“USPTO”) has granted patent number 9,839,612 B2 for the use of DehydraTECHTM technology as a delivery platform for a wide variety of Active Pharmaceutical Ingredients (“APIs”)

Emblem Announces Exclusive Agreement with Canntab Therapeutics for Cannabinoid Based Oral Sustained Release Formulation

Emblem Announces Exclusive Agreement with Canntab Therapeutics for Cannabinoid Based Oral Sustained Release Formulation

Emblem Corp. (TSXV:EMC) (EMC.WT) (“Emblem” or the “Company”) announced today that it has entered into a Collaboration and Licensing Agreement (the “Agreement”) with Canntab Therapeutics Limited (“Canntab”) of Toronto. Canntab has developed a patent-pending oral sustained release formulation for cannabinoids (the “Sustained Release Product” or the “Product”). Under the Agreement,

The Potential of Transdermal Drug Delivery

The Potential of Transdermal Drug Delivery

Drugs with low oral bioavailability risk failure in clinical trial: minimal absorption, after all, can translate to reduced efficacy. As a result, pharmaceutical companies look for alternative drug delivery methods.

Dipexium and PLx Pharma Announce Merger Agreement

Dipexium Pharmaceuticals and PLx Pharma, a privately held late-stage specialty pharmaceutical company, announced today that they have entered into a definitive agreement under which PLx Pharma will merge with a wholly-owned subsidiary of Dipexium in an all-stock transaction.

Are You Aware of the FDA's Plans for 2018?

Find out what's going on in our new report
 
Enter Your Log In Credentials
This setting should only be used on your home or work computer.

×

Privacy & Legal Policy

Privacy Policy

×
Investing News Network

Send this to a friend

Hi,
I thought you might find this interesting:
Cannabis Weekly Round-Up: Two Provinces Reveal Deals in Place for Recreational Market

URL: https://investingnews.com/daily/resource-investing/agriculture-investing/cannabis-investing/cannabis-weekly-roundup/